Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

6.01
Delayed Data
As of Jul 22
 -0.15 / -2.44%
Today’s Change
3.61
Today|||52-Week Range
11.15
-1.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$420.4M

Company Description

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for the treatment of cancer. Its products are therapeutic agents, which are designed to target cancer and imaging agents, which enables clinicians and patients to visualize and manage their disease. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in Tarrytown, NY.

Contact Information

Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown New York 10591
P:(914) 789-2800
Investor Relations:

Employees

Shareholders

Other institutional44.24%
Mutual fund holders42.86%
Individual stakeholders15.18%

Top Executives

Mark Robert BakerPresident, Chief Executive Officer & Director
Meryl J. LongvalHead-Operations
Patrick FabbioChief Financial Officer & Senior Vice President
Sheldon HirtExecutive Vice President & General Counsel
Vivien WongVice President-Product Development